A randomized controlled trial will test whether two doses of psilocybin (25 mg followed by either 25 or 30 mg), given with non-directive support, reduce obsessive-compulsive disorder (OCD) symptoms more than a single dose or a waitlist control. Thirty adults with treatment-refractory OCD will be enrolled. OCD symptoms will be measured with the Yale-Brown Obsessive-Compulsive Scale – Second Edition by a blinded rater at baseline and after the second dosing week. Participants will be followed for up to 12 months. The trial also aims to identify psychological mechanisms that may explain psilocybin's effects on OCD.
About 30-50% of people with obsessive-compulsive disorder do not respond to standard treatments. Recent pilot data suggest benefit from both psilocybin-assisted psychotherapy and imagery rescripting. Both interventions appear to allow reprocessing of negative emotions and core beliefs linked to past aversive events. The authors propose that basing psilocybin-assisted psychotherapy on an imagery rescripting framework may provide synergistic benefits in reducing symptoms, modifying core beliefs, and supporting value-based living.
A correction notice addresses an error in a previously published article on psilocybin therapy for obsessive-compulsive disorder. The notice specifies that the original article's DOI is 10.3389/fpsyt.2023.1278823 and provides the necessary correction. No findings, methods, or results are presented in this text.